Discussions

Our anti-VISTA monoclonal antibody program aims to develop monoclonal antibodies that could recognize and, potentially, against the immune checkpoint - VISTA (V-domain Ig suppressor of T cell activation). The development of such antibodies is still in the preliminary stage. We believe our program is unique and a leading program in the current biopharmaceutical market. Learn more about Next-IO™ Anti-VISTA Monoclonal Antibody Program: https://www.creative-biolabs.com/immuno-oncology/anti-vista-monoclonal-antibody-program.htm